Your browser doesn't support javascript.
loading
Recent progress in the use of pharmacotherapy for endometrial cancer.
Giudice, Elena; Salutari, Vanda; Ricci, Caterina; Nero, Camilla; Carbone, Maria Vittoria; Musacchio, Lucia; Ghizzoni, Viola; Perri, Maria Teresa; Camarda, Floriana; Tronconi, Francesca; Lorusso, Domenica; Scambia, Giovanni.
Afiliación
  • Giudice E; Institute of Obstetrics and Gynecology, Università Cattolica del Sacro Cuore, Rome, Italy.
  • Salutari V; Department of Woman, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
  • Ricci C; Department of Woman, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
  • Nero C; Department of Woman, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
  • Carbone MV; Department of Woman, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
  • Musacchio L; Department of Woman, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
  • Ghizzoni V; Institute of Obstetrics and Gynecology, Università Cattolica del Sacro Cuore, Rome, Italy.
  • Perri MT; Institute of Obstetrics and Gynecology, Università Cattolica del Sacro Cuore, Rome, Italy.
  • Camarda F; Medical Oncology, Università Cattolica del Sacro Cuore, Rome, Italy.
  • Tronconi F; Department of Medical Oncology, Università Politecnica delle Marche, Ancona, Italy.
  • Lorusso D; Institute of Obstetrics and Gynecology, Università Cattolica del Sacro Cuore, Rome, Italy.
  • Scambia G; Department of Woman, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Expert Opin Pharmacother ; 24(1): 83-94, 2023 Jan.
Article en En | MEDLINE | ID: mdl-35912837
ABSTRACT

INTRODUCTION:

Endometrial cancer (EC) is the most common gynecological cancer in developed countries. The ESGO/ESTRO/ESP updated evidence-based guidelines in 2020, introducing molecular classification to guide EC treatment. The genomic-based approach has identified four prognostic subgroups of EC. Each of these may benefit from a tailored treatment depending on the molecular profile, the histotype, and stage of disease for the adjuvant and the metastatic/recurrent setting. Several clinical trials are now ongoing to identify the best treatment according to the molecular profile of EC. AREAS COVERED This review analyzes tailored treatment for EC according to the molecular profile, both in the adjuvant and in the metastatic/recurrent setting. The authors review the results of clinical studies and highlight ongoing trials. EXPERT OPINION Several new agents are under evaluation in order to personalize EC treatment according to specific molecular profiles in the adjuvant, advanced, and recurrent settings. Clinical trials investigating the impact of molecular classification have yielded encouraging results. EC can no longer be considered a single tumor entity susceptible to a single treatment modality but rather be split into four distinct types, requiring tailored treatments.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Asunto principal: Neoplasias Endometriales Tipo de estudio: Guideline Límite: Female / Humans Idioma: En Revista: Expert Opin Pharmacother Asunto de la revista: FARMACOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Italia

Texto completo: 1 Colección: 01-internacional Asunto principal: Neoplasias Endometriales Tipo de estudio: Guideline Límite: Female / Humans Idioma: En Revista: Expert Opin Pharmacother Asunto de la revista: FARMACOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Italia